Journal article
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Abstract
PurposeGTI-2040 is a novel antisense oligonucleotide to the R2 subunit of ribonucleotide reductase. This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC).MethodsChemo-naïve CRPC patients with adequate performance status and organ function were treated with docetaxel 75 mg/m2 IV on day 1 …
Authors
Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P
Journal
Cancer Chemotherapy and Pharmacology, Vol. 67, No. 4, pp. 927–933
Publisher
Springer Nature
Publication Date
April 2011
DOI
10.1007/s00280-010-1389-7
ISSN
0344-5704